Nebivolol Actavis

Nebivolol, the active ingredient in Nebivolol Actavis, is a beta‑blocker presented as an oral tablet for oral use. It lowers elevated blood pressure and is indicated for the management of hypertension in adult patients.

GNH USA supplies Nebivolol Actavis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU GMP guidelines and provides batch‑tested products with full documentation for regulatory submissions. Clients benefit from reliable logistics, temperature‑controlled shipping where required, and dedicated technical support throughout the procurement process.

Nebivolol is a selective β1‑adrenergic blocker used in the management of cardiovascular conditions, primarily hypertension. - Hypertension: lowers systolic and diastolic blood pressure in adults with primary hypertension. - Heart failure: improves cardiac output and may reduce symptoms when used as part of standard heart‑failure therapy. - Chronic stable angina: may reduce myocardial oxygen demand by decreasing heart rate and blood pressure.

Nebivolol is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Fatigue: feeling of tiredness or lack of energy. - Headache: mild to moderate cranial pain. - Dizziness: sensation of light‑headedness, especially on standing. - Bradycardia: slower than normal heart rate. - Nausea: upset stomach, sometimes with mild vomiting. - Nasal congestion: blocked or runny nose.

Serious or Rare Side Effects: - Severe bradycardia: markedly low heart rate requiring medical attention. - Hypotension: dangerously low blood pressure causing faintness. - Heart block: impaired electrical conduction in the heart. - Bronchospasm: narrowing of airways, especially in patients with asthma. - Allergic reaction: rash, itching, swelling, or anaphylaxis. - Hepatic injury: abnormal liver function tests or jaundice.

Nebivolol should be used with careful clinical assessment and monitoring. - Blood pressure monitoring: regularly check to ensure therapeutic targets are met. - Cardiac function assessment: evaluate heart rate and ECG, especially in patients with conduction disorders. - Asthma/COPD caution: avoid in patients with severe bronchospastic disease. - Discontinuation: taper gradually to prevent rebound hypertension. - Renal impairment: adjust dose in patients with reduced kidney function. - Store at below 25°C: keep in the original pack, protect from moisture.

Nebivolol may interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Other beta‑blockers: additive bradycardia and hypotension. - Calcium‑channel blockers (verapamil, diltiazem): increased risk of severe bradycardia. - Potent CYP2D6 inhibitors (paroxetine, fluoxetine): may raise nebivolol plasma levels.

Moderate Interactions (Monitor Closely):\n- Diuretics: may enhance antihypertensive effect, requiring BP monitoring. - ACE inhibitors or ARBs: combined effect on blood pressure, watch for hypotension. - NSAIDs: can blunt antihypertensive response. - Antiarrhythmic agents: may affect cardiac conduction. - Antidiabetic drugs: monitor glucose as beta‑blockade can mask hypoglycemia signs.